Arix co-leads EUR 20 million Series A investment round for STipe Therapeutics

  • Further strengthens position in oncology; investment in STipe increases oncology portfolio to six companies
  • Dr Christian Schetter, Entrepreneur in Residence at Arix Bioscience, joins STipe as Executive Chairman

LONDON, 30 September 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today announces it has co-led the investment in a new portfolio company STipe Therapeutics (“STipe”), founded to exploit a novel mechanism in the Stimulator of Interferon Genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders.

Dr Christian Schetter, Entrepreneur in Residence at Arix, will join the company as Executive Chairman and Jonathan Tobin, Investment Director at Arix, will join STipe’s board of directors.

Read more